149 related articles for article (PubMed ID: 8809640)
21. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
22. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
23. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic administration of granulocyte colony-stimulating factor when monocytopenia appears lessens neutropenia caused by chemotherapy for lung cancer.
Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
Am J Clin Oncol; 2000 Jun; 23(3):278-82. PubMed ID: 10857893
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
[TBL] [Abstract][Full Text] [Related]
27. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy.
Glaspy JA; Bleecker G; Crawford J; Stoller R; Strauss M
Eur J Cancer; 1993; 29A Suppl 7():S23-30. PubMed ID: 7508727
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
Riikonen P; Rahiala J; Salonvaara M; Perkkiƶ M
Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
Drummond M; Davies L
Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
[TBL] [Abstract][Full Text] [Related]
31. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
32. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience.
Renwick W; Pettengell R; Green M
BioDrugs; 2009; 23(3):175-86. PubMed ID: 19627169
[TBL] [Abstract][Full Text] [Related]
33. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer.
Repetto L; Biganzoli L; Koehne CH; Luebbe AS; Soubeyran P; Tjan-Heijnen VC; Aapro MS
Eur J Cancer; 2003 Nov; 39(16):2264-72. PubMed ID: 14556916
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy.
Crawford J
Pharmacotherapy; 2003 Aug; 23(8 Pt 2):15S-19S. PubMed ID: 12921218
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer.
Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC
J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
[TBL] [Abstract][Full Text] [Related]
37. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
38. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Bohlius J; Reiser M; Schwarzer G; Engert A
Cochrane Database Syst Rev; 2004; (3):CD003189. PubMed ID: 15266474
[TBL] [Abstract][Full Text] [Related]
39. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
40. A predictive model for neutropenia associated with cancer chemotherapy.
Lyman GH
Pharmacotherapy; 2000 Jul; 20(7 Pt 2):104S-111S. PubMed ID: 10905685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]